Quintrio
Home

PHARMACEUTICAL PREPARATIONS

Equillium, Inc. Common Stock

EQ

Equillium Inc is a biotechnology innovator developing novel therapies to treat severe autoimmune and inflammatory disorders with the mission to develop life-changing therapeutics for patients. It primary goal is to advance EQ504, a novel aryl hydrocarbon receptor, or AhR, modulator, into and through clinical development. The Company operates through a single operating and reportable segment focused on the business of developing novel therapies to treat severe autoimmune and inflammatory disorders, with the mission to develop life-changing therapeutics for patients. The Company manages all business activities on a consolidated basis.

Last trade $1.17
Day change +$0.015 (+1.30%)
Day range $1.15 – $1.22
Volume 493,549
Market cap $95M

Open XNAS

Fundamentals

Key company ratios and reported financial statements.

Source: Massive.com

Key ratios

Valuation

Market capitalization
$94.67M
Price / earnings
—
Price / book
1.8×
Price / sales
—
EV / sales
—
EV / EBITDA
-2.1×

Profitability

Earnings per share
-$0.22
Return on assets
-32.89%
Return on equity
-34.84%
Dividend yield
0%

Liquidity and leverage

Debt / equity
0×
Current ratio
19.49×
Quick ratio
19.49×
Cash ratio
18.92×

Cash flow

Price / cash flow
—
Price / free cash flow
—
Free cash flow
-$15.48M

Ratios use trailing-twelve-month financials and market data as of Nov 16, 2026.

Financial statements

Income and cash flow amounts are for the period; balance sheets are point-in-time snapshots. Amounts are shown in USD. Latest 8 quarterly or 5 annual periods are displayed when available.

Income statement for EQ, quarterly periods
Line itemQ3 FY2026 Sep 30, 2026Q2 FY2026 Jun 30, 2026Q1 FY2026 Mar 31, 2026Q4 FY2025 Dec 31, 2025Q3 FY2025 Sep 30, 2025Q2 FY2025 Jun 30, 2025Q1 FY2025 Mar 31, 2025Q4 FY2024 Dec 31, 2024
Revenue$0$0$0$0$0$0$0$4.39M
Cost of revenue$0$0$0$0$0$0$0$0
Gross profit$0$0$0$0$0$0$0$4.39M
Selling, general and administrative$2.56M$2.41M$2.62M$2.43M$3.27M$2.15M$2.95M$1.78M
Research and development$2.49M$2.75M$2.99M$1.54M$1.3M$4.08M$5.92M$7.32M
Total operating expenses$5.05M$5.16M$5.61M$3.96M$4.58M$6.23M$8.87M$9.09M
Operating income-$5.05M-$5.16M-$5.61M-$3.96M-$4.58M-$6.23M-$8.87M-$4.7M
Interest expense$0$0$0$0$0$0$0$0
Income before taxes-$4.58M-$4.69M-$5.31M-$3.78M-$4.23M-$5.74M-$8.65M-$5.43M
Income taxes$0$0$0$0$0$0$0$361K
Net income-$4.58M-$4.69M-$5.31M-$3.78M-$4.23M-$5.74M-$8.65M-$5.79M
Net income attributable to common shareholders-$4.58M-$4.69M-$5.3M-$3.78M-$4.23M-$5.74M-$8.7M-$5.79M
EBITDA-$5.02M-$5.13M-$5.59M-$3.94M-$4.55M-$6.2M-$8.84M-$4.66M
Basic earnings per share-$0.04-$0.04-$0.06-$0.04-$0.06-$0.16-$0.24-$0.16
Diluted earnings per share-$0.04-$0.04-$0.06-$0.04-$0.06-$0.16-$0.24-$0.17

Recent news

Company coverage with links to the original publishers.

Publication times in UTC
GlobeNewswire Inc.

Wereldhave, through Wereldhave Belgium, acquires supermarket unit and completes ownership of shopping center Ville2 in Charleroi

Wereldhave Belgium has acquired a supermarket anchor unit in shopping center Ville2 in Charleroi, achieving 100% ownership of the property. The acquisition was financed through newly issued Wereldhave N.V. shares at market value and will have a slightly positive impact on the group's LTV ratio, reducing it by 10 basis points to 42.4%.

GlobeNewswire Inc.

Equillium to Host Ulcerative Colitis KOL Event on November 5, 2025

Equillium will host a virtual key opinion leader event discussing unmet needs in ulcerative colitis treatment, featuring experts who will explore the potential of AhR modulation and the company's EQ504 therapeutic approach.

Dividends

Declared distributions and recorded event dates. Forecasts are not shown.

Updated daily

No declared upcoming dividend found.

Ex-dividendAmount / sharePay dateType
Jun 12, 2009$0.6875Jun 30, 2009recurring
Mar 13, 2009$0.6875Mar 31, 2009recurring
Dec 8, 2008$0.6875Dec 31, 2008recurring
Sep 5, 2008$0.6875Sep 30, 2008recurring
Jun 5, 2008$0.6875Jun 30, 2008recurring

Stock splits

Historical share-structure events and their execution dates.

Updated daily

No stock split records found.